Richard Klausner | |
|---|---|
 | |
| 11th Director of the National Cancer Institute | |
| In office August 1, 1995 –September 30, 2001 | |
| President | Bill Clinton George W. Bush |
| Preceded by | Samuel Broder |
| Succeeded by | Andrew C. von Eschenbach |
| Personal details | |
| Children | 4 |
| Alma mater | |
| Scientific career | |
| Institutions | |
Richard D. Klausner is an American scientist who served as the 11th director of the National Cancer Institute of the United States.
Klausner was born in 1950or1951. [1] His father was a chemist, and Klausner would visit his father's laboratory as a child. He began studying physics at Yale University, but changed his focus to biology, with the plan of becoming a doctor in a rural area. [1] Klausner received his MD from Duke Medical School in 1976. [2]
In 1979, Klausner joined the National Institutes of Health (NIH) as a postdoctoral fellow. At age 30, Klausner was appointed to the chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development. [1]
In 1992, he directed the review of the NIH's intramural research programs, in which he recommended sweeping changes. [1] He served as the director of the National Cancer Institute from 1995 to 2001, where he managed a staff of 5,000 employees and a budget of $4.5 billion. [3] In total, he spent more than 20 years at the NIH. [4]
He left the NCI to become the founding director of the Case Institute of Health, Science and Technology of the Case Foundation. [4] [5]
He was the managing partner of the biotech venture capital firm, the Column Group. [6] From 2002 to 2005, he was the executive director of the Bill & Melinda Gates Foundation. [3] [7]
He was a member of the Searle Scholars advisory board. [8] He was a scientific advisor at the Fred Hutchinson Cancer Research Center. [9] He has been an Advisor to the Presidents of the Academies for counter-terrorism and a liaison to the White House Office of Science & Technology Policy, [6] and was the chief strategy advisor for USAID. [10]
Klausner co-founded Juno Therapeutics in 2013, GRAIL in 2015. [11] [12] and MindStrong Health in 2014. He was the chief medical officer of Illumina from 2013 to 2016. [13]
In 2022, Klausner co-founded Altos Labs and is currently Chief Scientist and Board Co-Chairman of the company. [14]
He was president of the American Society for Clinical Investigation from 1995 to 1996. [12]
His research focused on T cells and the potential for CAR-T therapies. [15] He also has published research on the genetics of Von Hippel–Lindau disease, a condition which predisposes a person to developing cancer. [9] He is an author of more than 300 scientific articles. [6]
Klausner has two sons and twin daughters. [1]
| International | |
|---|---|
| National | |
